Incidence of T315I mutation in BCR/ABL-positive CML and ALL patients

Abstract

OBJECTIVES: Targeted therapy of Philadelphia-positive ALL and CML patients using imatinib (IM) has caused significant changes in treatment course and has increased the survival of patients. A small group of patients show resistance to IM. Acquired mutations in tyrosine kinase domain of BCR-ABL protein are a mechanism for development of resistance. T315I is one of the most common acquired mutations in this domain, which occurs in ATP binding site and inhibits the formation of hydrogen bond with IM. The aim of this study was to evaluate the prevalence of this mutation in BCR/ABL-positive CML and ALL patients.

METHODS: To conduct this study, 60 BCR-ABL-positive patients (including 50 CML and 10 ALL patients) who were subject to treatment with IM were selected. After taking the samples, presence of T315I mutation was assessed using ARMS-PCR on cDNA and its polymorphism was evaluated by sequencing.

RESULTS: The results showed that among 60 patients, only three patients had T315I mutation, which was detected using ARMS technique. The three patients bearing mutation were afflicted with CML and no significant association was found between blood parameters with duration of treatment in presence of mutation.

CONCLUSIONS: The mutation was found in three CML patients, which indicated lower likelihood and diagnostic value of this mutation in ALL patients. Given the negative direct sequencing results in T315I patients, it can be concluded that ARMS-PCR is a more sensitive technique when the number of cancer cells is low in patients during treatment.

Key words： BCR-ABL; T315I mutation; imatinib; CML; ALL

Abbreviations

JAK-STAT: Janus kinases/signal transducers and activators of transcription; MAPK: Mitogen-activated protein kinase; NF-kB: Nuclear factor kB; PI-3 kinase: Phosphatidylinositol 3-kinase.

Acknowledgements

This work was financially supported by grant TH94/8 from the Vice Chancellor for Research Affairs of the Ahvaz Jundishapur University of Medical Sciences. This paper is issued from the thesis of Fatemeh Norozi.

Compliance with ethics guidelines

The authors declare that they have no conflict of interest. All the procedures performed in the studies involving human participants were in accordance with the ethical standards of local ethics committee of the Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1394.342) as well as 1964 Helsinki declaration. Written informed consent was obtained from all patients and normal subjects.

References

1 Apperley J F (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol, 8(11): 1018–1029

PMID

2 Bhojwani D, Yang J J, Pui C H (2015). Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am, 62(1): 47–60

PMID

3 Branford S, Melo J V, Hughes T P (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood, 114(27): 5426–5435

PMID

4 Chomel J C, Sorel N, Bonnet M L, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan A G (2010). Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma, 51(11): 2103–2111

PMID

5 Donato N J, Wu J Y, Stapley J, Lin H, Arlinghaus R, Aggarwal B B, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M (2004). Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res, 64(2): 672–677

PMID

6 Druker B J, Guilhot F, O’Brien S G, Gathmann I, Kantarjian H, Gattermann N, Deininger M W, Silver R T, Goldman J M, Stone R M, Cervantes F, Hochhaus A, Powell B L, Gabrilove J L, Rousselot P, Reiffers J, Cornelissen J J, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J L, Radich J P, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R A, and the IRIS Investigators (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23): 2408–2417

PMID

7 Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J, Lydon N B (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2(5): 561–566

PMID

8 Ernst T, Hoffmann J, Erben P, Hanfstein B, Leitner A, Hehlmann R, Hochhaus A, Müller M C (2008). ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 93(9):1389–1393

9 Ernst T, La Rosée P, Müller M C, Hochhaus A (2011). BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am, 25(5): 997–1008, v–vi

PMID

10 Faderl S, Jeha S, Kantarjian H M (2003). The biology and therapy of adult acute lymphoblastic leukemia. Cancer, 98(7): 1337–1354

PMID

11 Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293(5531): 876–880

PMID

12 Hochhaus A, Kreil S, Corbin A S, La Rosüe P, Müller M C, Lahaye T, Hanfstein B, Schoch C, Cross N C, Berger U, Gschaidmeier H, Druker B J, Hehlmann R (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16(11): 2190–2196

PMID

13 Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross N C, Druker B J, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton J H, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J M (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1): 28–37

PMID

14 Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, Martinelli G (2012). Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. Blood Cancer J, 2(3): e61

PMID

15 Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O’Brien S, Ravandi F, Borthakur G, Cortes J (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 112(1): 53–55

PMID

16 Jabbour E, Soverini S (2009). Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol, 46(suppl 3): s22–26

17 Kagita S, Uppalapati S, Jiwatani S, Linga V G, Gundeti S, Nagesh N, Digumarti R (2014). Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol, 35(7): 7187–7193

PMID

18 Khorashad J S, Kelley T W, Szankasi P, Mason C C, Soverini S, Adrian L T, Eide C A, Zabriskie M S, Lange T, Estrada J C, Pomicter A D, Eiring A M, Kraft I L, Anderson D J, Gu Z, Alikian M, Reid A G, Foroni L, Marin D, Druker B J, O’Hare T, Deininger M W (2013). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3): 489–498

PMID

19 Kimura S, Ando T, Kojima K (2014). Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol, 19(1): 3–9

PMID

20 La Rosée P, Deininger M W (2010). Resistance to imatinib: mutations and beyond. Semin Hematol, 47(4): 335–343

21 La Starza R, Testoni N, Lafage-Pochitaloff M, Ruggeri D, Ottaviani E, Perla G, Martelli MF, Marynen P, Mecucci C(2002). Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. Haematologica, 87(2):143–147

22 Maru Y (2012). Molecular biology of chronic myeloid leukemia. Cancer Sci, 103(9): 1601–1610

PMID

23 Nicolini F E, Mauro M J, Martinelli G, Kim D W, Soverini S, Müller M C, Hochhaus A, Cortes J, Chuah C, Dufva I H, Apperley J F, Yagasaki F, Pearson J D, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman J M, Zhou W (2009). Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 114(26): 5271–5278

PMID

24 O’Hare T, Shakespeare W C, Zhu X, Eide C A, Rivera V M, Wang F, Adrian L T, Zhou T, Huang W S, Xu Q, Metcalf C A 3rd, Tyner J W, Loriaux M M, Corbin A S, Wardwell S, Ning Y, Keats J A, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer T K, Dalgarno D C, Deininger M W, Druker B J, Clackson T (2009). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5): 401–412

PMID

25 Quintás-Cardama A, Cortes J (2008). Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res, 14(14): 4392–4399

PMID

26 Roche-Lestienne C, Laï J L, Darré S, Facon T, Preudhomme C(2003). A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med, 348(22): 2265–2266

PMID

27 Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305(5682): 399–401

PMID

28 Soverini S, Iacobucci I, Baccarani M, Martinelli G (2007). Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica, 92(4): 437–439

PMID

29 Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H, Itoh K, Nishiwaki K, Suzuki K, Nagao R, Yao H, Hayashi Y, Satake S, Hirai H, Sawada K, Ottmann O G, Melo J V, Maekawa T (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett, 312(2): 228–234

PMID

30 Weisberg E, Manley P W, Breitenstein W, Brüggen J, Cowan-Jacob S W, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung A L, Mestan J, Daley G Q, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright R D, Gilliland D G, Griffin J D (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7(2): 129–141

PMID